Evaluating Treatment Algorithms for the Management of Patients With Type 2 Diabetes Mellitus: A Perspective on the Definition of Treatment Success
- 30 April 2011
- journal article
- review article
- Published by Elsevier BV in Clinical Therapeutics
- Vol. 33 (4), 408-424
- https://doi.org/10.1016/j.clinthera.2011.04.008
Abstract
No abstract availableKeywords
This publication has 80 references indexed in Scilit:
- Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)The Lancet, 2009
- Trajectories of glycaemia, insulin sensitivity, and insulin secretion before diagnosis of type 2 diabetes: an analysis from the Whitehall II studyThe Lancet, 2009
- Liraglutide, a once‐daily human GLP‐1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD‐1 SU)Diabetic Medicine, 2009
- Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysisCMAJ : Canadian Medical Association Journal, 2009
- 10-Year Follow-up of Intensive Glucose Control in Type 2 DiabetesNew England Journal of Medicine, 2008
- Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority studyThe Lancet, 2008
- Family physician and endocrinologist coordination as the basis for diabetes care in clinical practiceBMC Endocrine Disorders, 2008
- Glucose‐lowering activity of the dipeptidyl peptidase‐4 inhibitor saxagliptin in drug‐naive patients with type 2 diabetes*Diabetes, Obesity and Metabolism, 2008
- Effect of a Multifactorial Intervention on Mortality in Type 2 DiabetesNew England Journal of Medicine, 2008
- Efficacy and safety of the dipeptidyl peptidase‐4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double‐blind, non‐inferiority trialDiabetes, Obesity and Metabolism, 2007